Item 7.01. Regulation FD Disclosure.

On September 29, 2020, Eidos Therapeutics, Inc. (the "Company") began using an updated corporate presentation (the "Presentation"), a copy of which is furnished with this Current Report on Form 8-K as Exhibit 99.1. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1

The information responsive to Item 7.01 of the Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.



Exhibit
Number       Description

99.1           Presentation of Eidos Therapeutics, Inc., dated September 29, 2020

104          Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses